Table 2.
Results of the univariable Cox regression analysis for intrahepatic progression-free survival. CEA: carcinoembryogenic antigen, PVE: portal vein embolization.
| Factor | Hazard Ratio (95% Confidence Interval) | p Value |
|---|---|---|
| Age | 0.989 (0.959, 1.021) | 0.654 |
| Laterality of the primary colorectal cancer (right-sided vs. left-sided) | 2.242 (1.125, 4.465) | 0.022 |
| Location of the primary tumor (colon vs. rectal cancer) | 0.674 (0.363, 1.250) | 0.211 |
| Time interval between diagnosis of the primary colorectal cancer and detection of hepatic metastases (synchronous vs. metachronous) | 3.114 (0.932, 10.409) | 0.065 |
| Size of the largest metastasis at baseline | 1.021 (0.904, 1.153) | 0.736 |
| Number of metastases at baseline | 0.998 (0.905, 1.102) | 0.974 |
| Presence or absence of metastases in the FLR | 1.402 (0.771, 2.547) | 0.268 |
| Preoperative serum CEA level | 1.000 (1.000,1.000) | 0.736 |
| Time between PVE and right hemihepatectomy | 1.002 (0.995, 1.009) | 0.534 |
| Neoadjuvant chemotherapy prior to surgery | 1.539 (0.797, 2.970) | 0.199 |
| Adjuvant chemotherapy after surgery | 1.538 (0.740, 3.197) | 0.248 |
| Presence of extrahepatic disease | 1.712 (0.860, 3.410) | 0.126 |